Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Prajakti A, Kothare"'
Autor:
Chi‐Chung Li, Tiffini Voss, Ken Kowalski, Bei Yang, Huub Jan Kleijn, Christopher J. Jones, Rolien Bosch, David Michelson, Matthew DeAngelis, Yang Xu, Iris Xie, Prajakti A. Kothare
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 482-490 (2020)
Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure‐response (E‐R) m
Externí odkaz:
https://doaj.org/article/eb872eb56df648a2b8a35bd1a4180f5a
Autor:
Bei Yang, Prajakti A. Kothare, Tiffini Voss, Iris Xie, Chi-Chung Li, Yang Xu, Matthew DeAngelis, David Michelson, Ken Kowalski, Christopher Jones, Rolien Bosch, Huub Jan Kleijn
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 482-490 (2020)
Clinical and Translational Science
Clinical and Translational Science
Ubrogepant (MK‐1602) is a novel, oral, calcitonin gene‐related peptide receptor antagonist in clinical development with positive phase III outcomes for acute treatment of migraine. This paper describes the population exposure‐response (E‐R) m
Publikováno v:
Current drug metabolism. 22(10)
Background: Letermovir is approved for prophylaxis of cytomegalovirus infection and disease in cytomegalovirus-seropositive hematopoietic stem-cell transplant (HSCT) recipients. Objective: HSCT recipients are required to take many drugs concomitantly
Autor:
Marissa F. Dockendorf, Kevin P. Bateman, Iris Xie, Matthew Moyer, Jane Harrelson, Gowri Murthy, Andra Goldman, Jyoti Shah, Melanie Anderson, Rachel Ruba, Rubi Burlage, Jeffrey R. Sachs, Lisa A. Shipley, Prajakti A. Kothare
Publikováno v:
Clinical Pharmacology and Therapeutics
Merck & Co, Inc (Kenilworth, NJ) is investing in approaches to enrich clinical trial data and augment decision making through use of digital health technologies, outpatient sampling, and real‐time data access. As part of this strategy, a phase I st
Autor:
DG Krefetz, Prajakti A. Kothare, J Cote, Agh Ederveen, MV Chakravarthy, AW Krug, Radha Railkar, BJ Musser, Daniel Tatosian, AL Free, Pavan Vaddady, E DeNoia, Linda Morrow, Eunkyung Kauh
Publikováno v:
Clinical and Translational Science. 10:404-411
GPR40 mediates free fatty acid-induced insulin secretion in beta cells. We investigated the safety, pharmacokinetics, and glucose response of MK-8666, a partial GPR40 agonist, after once-daily multiple dosing in type 2 diabetes patients. This double-
Autor:
Julie A. Stone, Marissa F. Dockendorf, Kevin P. Bateman, Eric Woolf, Lisa A. Shipley, Yang Xu, Prajakti A. Kothare
Publikováno v:
The AAPS Journal
Dried blood spot (DBS) sample collection has gained increased interest across the pharmaceutical industry as a potential alternative to plasma for pharmacokinetic (PK) evaluations. However, regulatory guidelines and examples of late-stage clinical tr
Autor:
Eric M. Parker, Sandra A.G. Visser, Maria E. Trujillo, Mallika Lala, Matthew L. Rizk, Tjerk Bueters, Daniel Tatosian, Christopher R. Gibson, Prajakti A. Kothare, Pavan Vaddady
Publikováno v:
Early Drug Development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::24981f06c4f8ea76f82aa36ec113d0cd
https://doi.org/10.1002/9783527801756.ch17
https://doi.org/10.1002/9783527801756.ch17
Publikováno v:
Clinical Pharmacology & Therapeutics. 106:45-46
Publikováno v:
Clinical pharmacology and therapeutics. 104(6)
Advances in emerging innovative technologies have led to optimistic outlooks on their transformative potential for healthcare and clinical trials.1 Given the increased attention, this white paper by the International Consortium for Innovation and Qua
Autor:
Eugene E. Marcantonio, Ken Kowalski, Prajakti A. Kothare, Tiffini Voss, Iris Xie, Marissa F. Dockendorf, Huub Jan Kleijn, Kevin P. Bateman, Chi-Chung Li, Christopher Jones, Rolien Bosch, Bob Thornton, Bei Yang, Yang Xu
Publikováno v:
Journal of clinical pharmacology. 58(3)
Merck & Co., Inc. (Kenilworth, New Jersey) has recently published an integrated strategy for implementation of dried blood spots (DBS) in late-stage trials for population pharmacokinetic (PK) modeling. We applied this strategy for another late-stage